Oral etoposide in the treatment of hormone‐refractory prostate cancer

Maha H. Hussain, Kenneth J. Pienta, Bruce G. Redman, Glenn D. Cummings, Lawrence E. Flaherty

Research output: Contribution to journalArticle

Abstract

Background. Hormone‐refractory prostate cancer generally remains a chemotherapy‐resistant tumor and therefore warrants the continued evaluation of promising agents. Methods. Twenty‐two eligible patients with hormone‐refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28‐day cycle. Response was evaluated using standard solid tumor response criteria. Results. There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overal 1‐year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted. Conclusions. Single‐agent oral etoposide has minimal activity in patients with hormone‐refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)100-103
Number of pages4
JournalCancer
Volume74
Issue number1
DOIs
StatePublished - Jul 1 1994
Externally publishedYes

    Fingerprint

Keywords

  • chemotherapy
  • hormone refractory prostate cancer
  • oral etoposide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this